Search Results - Accountancy

1

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

by N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov
Published 2019-01-01
“... share of direct medical treatment costs, are automatically accounted for 84 Russian regions (except...”

Get full text

Article
2

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer

by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
Published 2020-02-01
“... medications and adverse event treatments were considered. We accounted for treatment discontinuation and CDK4...”

Get full text

Article